Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitorsHitisha Patel, Teeru Bihani|Breast Cancer Research|2019Cited by 77
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancersTeeru Bihani, Celina M. D’Cruz|Oncotarget|2014Cited by 57
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D. Dubash, Shyamala Maheswaran, Joseph A. LiCausi et al.|Breast Cancer Research and Treatment|2023Cited by 6
Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutationsTaronish D. Dubash, Shyamala Maheswaran, Aditya Bardia et al.|Cancer Research|2020Cited by 2